Cover Image

Targeting the proteasome in advanced renal cell carcinoma: complexity and limitations of patient-individualized preclinical drug discovery

Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missin...

Full description

Saved in:
Bibliographic Details
Main Authors: Li, Jielin (Author) , Pohl, Laura (Author) , Schüler, Julia (Author) , Korzeniewski, Nina (Author) , Reimold, Philipp (Author) , Kaczorowski, Adam (Author) , Hou, Weibin (Author) , Zschäbitz, Stefanie (Author) , Nientiedt, Cathleen (Author) , Jäger, Dirk (Author) , Hohenfellner, Markus (Author) , Duensing, Anette (Author) , Duensing, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 31 May 2021
In: Biomedicines
Year: 2021, Volume: 9, Issue: 6, Pages: 1-12
ISSN:2227-9059
DOI:10.3390/biomedicines9060627
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/biomedicines9060627
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2227-9059/9/6/627
Get full text
Author Notes:Jielin Li, Laura Pohl, Julia Schüler, Nina Korzeniewski, Philipp Reimold, Adam Kaczorowski, Weibin Hou, Stefanie Zschäbitz, Cathleen Nientiedt, Dirk Jäger, Markus Hohenfellner, Anette Duensing and Stefan Duensing

MARC

LEADER 00000caa a2200000 c 4500
001 1766765491
003 DE-627
005 20230427034928.0
007 cr uuu---uuuuu
008 210813s2021 xx |||||o 00| ||eng c
024 7 |a 10.3390/biomedicines9060627  |2 doi 
035 |a (DE-627)1766765491 
035 |a (DE-599)KXP1766765491 
035 |a (OCoLC)1341420616 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Li, Jielin  |e VerfasserIn  |0 (DE-588)1166903915  |0 (DE-627)103077465X  |0 (DE-576)510958796  |4 aut 
245 1 0 |a Targeting the proteasome in advanced renal cell carcinoma  |b complexity and limitations of patient-individualized preclinical drug discovery  |c Jielin Li, Laura Pohl, Julia Schüler, Nina Korzeniewski, Philipp Reimold, Adam Kaczorowski, Weibin Hou, Stefanie Zschäbitz, Cathleen Nientiedt, Dirk Jäger, Markus Hohenfellner, Anette Duensing and Stefan Duensing 
264 1 |c 31 May 2021 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 13.08.2021 
520 |a Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missing. Patients and Methods: In vitro drug screening of tumor-derived short-term cultures obtained from seven patients with clear cell RCC was performed. For one patient, a patient-derived xenograft (PDX) mouse model was established for in vivo validation experiments. Drug effects were further investigated in established RCC cell lines. Results: The proteasome inhibitor carfilzomib was among the top hits identified in three of four patients in which an in vitro drug screening could be performed successfully. Carfilzomib also showed significant acute and long-term cytotoxicity in established RCC cell lines. The in vivo antitumoral activity of carfilzomib was confirmed in a same-patient PDX model. The cytotoxicity of carfilzomib was found to correlate with the level of accumulation of ubiquitinated proteins. Conclusions: In this proof-of-concept study, we show that patient-individualized in vitro drug screening and preclinical validation is feasible. However, the fact that carfilzomib failed to deliver a clinical benefit in RCC patients in a recent phase II trial unrelated to the present study underscores the complexities and limitations of this strategy. 
650 4 |a carfilzomib 
650 4 |a drug screening 
650 4 |a proteasome inhibitor 
650 4 |a renal cell carcinoma 
700 1 |a Pohl, Laura  |e VerfasserIn  |4 aut 
700 1 |a Schüler, Julia  |e VerfasserIn  |4 aut 
700 1 |a Korzeniewski, Nina  |e VerfasserIn  |0 (DE-588)1074043979  |0 (DE-627)830211845  |0 (DE-576)435550144  |4 aut 
700 1 |a Reimold, Philipp  |e VerfasserIn  |0 (DE-588)1205514376  |0 (DE-627)1691191469  |4 aut 
700 1 |a Kaczorowski, Adam  |e VerfasserIn  |0 (DE-588)1062747550  |0 (DE-627)806827742  |0 (DE-576)420146318  |4 aut 
700 1 |a Hou, Weibin  |d 1988-  |e VerfasserIn  |0 (DE-588)1170371841  |0 (DE-627)1038710928  |0 (DE-576)512500657  |4 aut 
700 1 |a Zschäbitz, Stefanie  |d 1983-  |e VerfasserIn  |0 (DE-588)1037698827  |0 (DE-627)75589894X  |0 (DE-576)391727206  |4 aut 
700 1 |a Nientiedt, Cathleen  |e VerfasserIn  |0 (DE-588)1162095288  |0 (DE-627)1025532813  |0 (DE-576)507145070  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Hohenfellner, Markus  |d 1958-  |e VerfasserIn  |0 (DE-588)133862518  |0 (DE-627)557857988  |0 (DE-576)300155263  |4 aut 
700 1 |a Duensing, Anette  |e VerfasserIn  |0 (DE-588)1186091703  |0 (DE-627)1665366486  |4 aut 
700 1 |a Duensing, Stefan  |d 1967-  |e VerfasserIn  |0 (DE-588)1074044487  |0 (DE-627)830213007  |0 (DE-576)435550098  |4 aut 
773 0 8 |i Enthalten in  |t Biomedicines  |d Basel : MDPI, 2013  |g 9(2021), 6, Artikel-ID 627, Seite 1-12  |h Online-Ressource  |w (DE-627)750370483  |w (DE-600)2720867-9  |w (DE-576)384589596  |x 2227-9059  |7 nnas  |a Targeting the proteasome in advanced renal cell carcinoma complexity and limitations of patient-individualized preclinical drug discovery 
773 1 8 |g volume:9  |g year:2021  |g number:6  |g elocationid:627  |g pages:1-12  |g extent:12  |a Targeting the proteasome in advanced renal cell carcinoma complexity and limitations of patient-individualized preclinical drug discovery 
856 4 0 |u https://doi.org/10.3390/biomedicines9060627  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2227-9059/9/6/627  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210813 
993 |a Article 
994 |a 2021 
998 |g 1074044487  |a Duensing, Stefan  |m 1074044487:Duensing, Stefan  |d 910000  |d 910200  |e 910000PD1074044487  |e 910200PD1074044487  |k 0/910000/  |k 1/910000/910200/  |p 13  |y j 
998 |g 1186091703  |a Duensing, Anette  |m 1186091703:Duensing, Anette  |d 910000  |d 910200  |e 910000PD1186091703  |e 910200PD1186091703  |k 0/910000/  |k 1/910000/910200/  |p 12 
998 |g 133862518  |a Hohenfellner, Markus  |m 133862518:Hohenfellner, Markus  |d 910000  |d 910200  |e 910000PH133862518  |e 910200PH133862518  |k 0/910000/  |k 1/910000/910200/  |p 11 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 10 
998 |g 1162095288  |a Nientiedt, Cathleen  |m 1162095288:Nientiedt, Cathleen  |d 910000  |d 910100  |e 910000PN1162095288  |e 910100PN1162095288  |k 0/910000/  |k 1/910000/910100/  |p 9 
998 |g 1062747550  |a Kaczorowski, Adam  |m 1062747550:Kaczorowski, Adam  |d 910000  |d 910200  |e 910000PK1062747550  |e 910200PK1062747550  |k 0/910000/  |k 1/910000/910200/  |p 6 
998 |g 1037698827  |a Zschäbitz, Stefanie  |m 1037698827:Zschäbitz, Stefanie  |d 910000  |d 910100  |e 910000PZ1037698827  |e 910100PZ1037698827  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 1205514376  |a Reimold, Philipp  |m 1205514376:Reimold, Philipp  |d 910000  |d 910200  |e 910000PR1205514376  |e 910200PR1205514376  |k 0/910000/  |k 1/910000/910200/  |p 5 
998 |g 1074043979  |a Korzeniewski, Nina  |m 1074043979:Korzeniewski, Nina  |d 50000  |e 50000PK1074043979  |k 0/50000/  |p 4 
999 |a KXP-PPN1766765491  |e 3967244342 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"display":"Li, Jielin","family":"Li","role":"aut","given":"Jielin"},{"display":"Pohl, Laura","family":"Pohl","given":"Laura","role":"aut"},{"given":"Julia","role":"aut","display":"Schüler, Julia","family":"Schüler"},{"role":"aut","given":"Nina","family":"Korzeniewski","display":"Korzeniewski, Nina"},{"role":"aut","given":"Philipp","family":"Reimold","display":"Reimold, Philipp"},{"family":"Kaczorowski","display":"Kaczorowski, Adam","given":"Adam","role":"aut"},{"role":"aut","given":"Weibin","display":"Hou, Weibin","family":"Hou"},{"family":"Zschäbitz","display":"Zschäbitz, Stefanie","given":"Stefanie","role":"aut"},{"role":"aut","given":"Cathleen","display":"Nientiedt, Cathleen","family":"Nientiedt"},{"role":"aut","given":"Dirk","family":"Jäger","display":"Jäger, Dirk"},{"family":"Hohenfellner","display":"Hohenfellner, Markus","role":"aut","given":"Markus"},{"family":"Duensing","display":"Duensing, Anette","given":"Anette","role":"aut"},{"family":"Duensing","display":"Duensing, Stefan","given":"Stefan","role":"aut"}],"id":{"eki":["1766765491"],"doi":["10.3390/biomedicines9060627"]},"name":{"displayForm":["Jielin Li, Laura Pohl, Julia Schüler, Nina Korzeniewski, Philipp Reimold, Adam Kaczorowski, Weibin Hou, Stefanie Zschäbitz, Cathleen Nientiedt, Dirk Jäger, Markus Hohenfellner, Anette Duensing and Stefan Duensing"]},"physDesc":[{"extent":"12 S."}],"relHost":[{"part":{"volume":"9","extent":"12","year":"2021","pages":"1-12","issue":"6","text":"9(2021), 6, Artikel-ID 627, Seite 1-12"},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Targeting the proteasome in advanced renal cell carcinoma complexity and limitations of patient-individualized preclinical drug discoveryBiomedicines","title":[{"title_sort":"Biomedicines","subtitle":"open access journal","title":"Biomedicines"}],"origin":[{"publisherPlace":"Basel","publisher":"MDPI","dateIssuedKey":"2013","dateIssuedDisp":"2013-"}],"pubHistory":["1.2013 -"],"note":["Gesehen am 12.08.20"],"id":{"eki":["750370483"],"zdb":["2720867-9"],"issn":["2227-9059"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"750370483"}],"recId":"1766765491","type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"31 May 2021","dateIssuedKey":"2021"}],"note":["Gesehen am 13.08.2021"],"title":[{"subtitle":"complexity and limitations of patient-individualized preclinical drug discovery","title_sort":"Targeting the proteasome in advanced renal cell carcinoma","title":"Targeting the proteasome in advanced renal cell carcinoma"}]} 
SRT |a LIJIELINPOTARGETINGT3120 

Similar Items